Patents by Inventor Anurschirwan Peyman

Anurschirwan Peyman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20030203896
    Abstract: The present invention relates to acylguanidino derivatives of formula (I), in which R1, R2, R3, A, B, X, Y and n have the meanings indicated in claim 1, their physiologically tolerable salts and their prodrugs. The compounds of the formula (I) are valuable pharmaceutically active compounds. They are vitronectin receptor antagonists and inhibitors of cell adhesion and bone resorption by osteoclasts. This renders them suitable, for example, for the therapy and prophylaxis of illness which are based on the interaction between vitronectin receptors and their ligands in cell-cell or cell-matrix interaction processes or which can be prevented, alleviated or cured by influencing such interactions. For example, they can be applied for treating and preventing osteoporosis, or for inhibiting undesired angiogenesis or proliferation of cells of the vascular smooth muscles.
    Type: Application
    Filed: January 27, 2003
    Publication date: October 30, 2003
    Inventors: Anurschirwan Peyman, David Will, Thomas R Gadek, Jochen Knolle, Robert McDowell, Jean-Francois Gourvest, Jean-Marie Ruxer
  • Patent number: 6602878
    Abstract: Acylquanidines of the formula wherein the substituents are defined as in the specification which are antagonists of the vitronectin receptor and inhibitors of cell adhesion and bone resorption mediated by the osteoclasts.
    Type: Grant
    Filed: June 27, 2001
    Date of Patent: August 5, 2003
    Assignees: Aventis Pharma S.A., Genentech, Inc.
    Inventors: Denis Carniato, Thomas R. Gadek, Jean-Francois Gourvest, Jochen Knolle, Anurschirwan Peyman, Jean-Marie Ruxer, Sarah C. Bodary
  • Patent number: 6586442
    Abstract: A compound of the formula wherein the substituents are as defined in the specification and its pharmaceutically acceptable salts and it prodrug useful for treating osteoporosis.
    Type: Grant
    Filed: June 26, 2002
    Date of Patent: July 1, 2003
    Inventors: Denis Carniato, Jean-Francois Gourvest, Jochen Knolle, Anurschirwan Peyman, Sarah C. Bodary, Thomas R. Gadek
  • Patent number: 6500815
    Abstract: The invention concerns compounds of formula (I) wherein: X, Y, R1, R2, Z, G are as defined in the description, the methods for preparing them and the intermediates in said method, their use as medicine and the pharmaceutical compositions containing them.
    Type: Grant
    Filed: December 17, 2001
    Date of Patent: December 31, 2002
    Assignees: Aventis Pharma S.A., Genentech
    Inventors: Denis Carniato, Thomas R. Gadek, Jochen Knolle, Jean-Francois Gourvest, Anurschirwan Peyman, Sarah C. Bodary
  • Publication number: 20020187976
    Abstract: A compound of the formula 1
    Type: Application
    Filed: June 26, 2002
    Publication date: December 12, 2002
    Applicant: Aventis Pharma S.A.
    Inventors: Denis Carniato, Jean-Francois Gourvest, Jochen Knolle, Anurschirwan Peyman, Sarah Bodary, Thomas R. Gadek
  • Patent number: 6458801
    Abstract: A compound of the formula wherein the substituents are as defined in the specification and its pharmaceutically acceptable salts and its prodrug useful for treating osteoporosis.
    Type: Grant
    Filed: June 29, 2001
    Date of Patent: October 1, 2002
    Assignees: Aventis Pharma S.A., Genentech, Inc.
    Inventors: Denis Carniato, Thomas R. Gadek, Jean-Francois Gourvest, Jochen Knolle, Anurschirwan Peyman, Sarah C. Bodary
  • Patent number: 6391904
    Abstract: A compound of the formula where the substituents are defined in the specification and its pharmaceutically acceptable salts and prodrugs thereof useful as antagonists of vitronectin receptors.
    Type: Grant
    Filed: June 29, 2001
    Date of Patent: May 21, 2002
    Assignees: Aventis Pharma S.A., Genentech, Inc.
    Inventors: Denis Carniato, Jean-Francois Gourvest, Jean-Marie Ruxer, Jochen Knolle, Anurschirwan Peyman, Sarah C. Bodary, Thomas R. Gadek
  • Patent number: 6339082
    Abstract: A compound selected from the group consisting of a compound of the formula wherein the substituents are defined as set forth in the specification and its salts with non-toxic pharmaceutically acceptable acids and bases useful for treating loss of bone matrix.
    Type: Grant
    Filed: June 29, 2000
    Date of Patent: January 15, 2002
    Assignees: Aventis Pharma S.A., Genetech, Inc.
    Inventors: Denis Carniato, Thomas R. Gadek, Jean-Francois Gourvest, Jochen Knolle, Robert S. McDowell, Anurschirwan Peyman